Leiden-based biotechnology company Mimetas has received 1.6 million USD funding for development of an organ-on-a-chip model for neurotoxicity. The aim of the project is to improve existing neurotoxicity tests and to reduce experimentation on animals. A panel of experts from BASF, Sanofi, GlaxoSmithKline, Abbvie, NC3Rs and renowned academic institutions has selected the Mimetas solution from a lineup of strong competitors. Mimetas will lead the consortium, which also includes the Institute for Risk Assessment Sciences (Utrecht, The Netherlands) and Cellular Dynamics International (Wisconsin, USA).
{iframe}http://www.b3cnewswire.com/201512221324/mimetas-and-partners-receive-16-million-dollar-industry-funding-for-development-of-organ-on-a-chip-neurotoxicity-models.html{/iframe}